Sanofi/AstraZeneca Win Beyfortus Approval To Prevent RSV In US Infants

Prophylactic Antibody A Key Asset In Sanofi’s Vaccine Portfolio

 
• By Mandy Jackson

Sanofi, which leads commercialization under its 2017 deal with AstraZeneca, may soon compete with a maternal RSV vaccine from Pfizer, but the US may have room for only one infant-protecting option.

Portrait of asian parent hands holding newborn baby
Beyfortus is approved for newborns and toddlers in their second RSV season • Source: Shutterstock

More from New Products

More from Scrip